Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
Receptors, Chimeric Antigen
T-Lymphocytes
Receptors, Antigen, T-Cell
chimeric antigen receptor T cell therapy
Immunotherapy, Adoptive
3. Good health
Cohort Studies
tisagenlecleucel
Japan
manufacturing failure
Risk Factors
Humans
Bendamustine Hydrochloride
Lymphoma, Large B-Cell, Diffuse
DOI:
10.1111/bjh.18831
Publication Date:
2023-04-25T12:45:47Z
AUTHORS (29)
ABSTRACT
Summary For successful chimeric antigen receptor T (CAR‐T) cell therapy, CAR‐T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B‐cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical between 30 cases that failed (7.4%) those succeeded ( n = 378). Among the failures, proportion of previously treated bendamustine (43.3% vs. 14.8%; p < 0.001) was significantly higher, their platelet counts (12.0 17.0 × 10 4 /μL; 0.01) CD4/CD8 T‐cell ratio (0.30 0.56; peripheral blood at apheresis were lower than group. Multivariate analysis revealed repeated use short washout periods prior (odds [OR], 5.52; 0.013 ≥6 cycles period 3–24 months; OR, 57.09; 0.005 ≥3 <3 months), low (OR, 0.495 per 5 0.022) or ratios (<one third) 3.249; 0.011) increased failure. Manufacturing remains an obstacle therapy DLBCL patients. Avoiding factors, such as administration sufficient washout, risk‐adapted strategies may help optimize
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (33)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....